Trial Profile

A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Margetuximab (Primary) ; Retifanlimab (Primary) ; Tebotelimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin; Trastuzumab
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms MAHOGANY
Sponsors MacroGenics

22 Apr 2025 Status changed from active, no longer recruiting to completed.
13 May 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2025.
12 Mar 2024 This trial has been completed in Italy, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com